NAMI
ACAD icon

Nomura Asset Management International’s Acadia Pharmaceuticals ACAD Stock Holding History

Nomura Asset Management International’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Hold
92,648
– – ﹤0.01% 1037
2026
Q1 		$2.06M Hold
92,648
– – ﹤0.01% 965
2025
Q4 		$2.48M Buy
+92,648
New +$2.21M ﹤0.01% 960

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nomura Asset Management International's ACAD Position: Q2 2026 in Review

Nomura Asset Management International held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 92,648 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Nomura Asset Management International first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.48M in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Nomura Asset Management International held 92,648 shares of Acadia Pharmaceuticals worth $2.34M as of Q2 2026.
  • Nomura Asset Management International left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Nomura Asset Management International's portfolio in Q2 2026, its #1037 holding.
  • Nomura Asset Management International first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nomura Asset Management International's Acadia Pharmaceuticals position peaked at $2.48M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.